Investment analysts at StockNews.com initiated coverage on shares of Advaxis (NASDAQ:ADXS – Get Rating) in a research report issued on Monday. The firm set a "sell" rating on the stock.

Advaxis Price Performance

Shares of NASDAQ ADXS opened at $1.73 on Monday. Advaxis has a 1 year low of $1.00 and a 1 year high of $11.18.

Advaxis Company Profile

(Get Rating)

Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.

Recommended Stories

• Get a free copy of the StockNews.com research report on Advaxis (ADXS)
• MarketBeat Week in Review – 2/27 – 3/3
• The 3 Most Upgraded Stocks Are Reversing
• How to Find Blue Chip Dividend Stocks
• Zscaler, Inc Plummets, Is It Time To Buy The Dip?
• What is a Good Dividend Yield? How to Decide

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.